PRESS RELEASE – UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute

MRI confirms complete healing of hamstring eight weeks after Dr. Wade McKenna administered guided injections of bone marrow aspirate concentrate (BMAC) harvested with BioMAC (patent pending) bone marrow aspiration cannula and AlphGEMS amniotic tissue product at the Riordan-McKenna Institute.

DALLAS-FORT WORTH, TEXAS (PRWEB) SEPTEMBER 03, 2015

Zack Bornstein with Dr. McKenna and Physicians Assistant, Troy Chandler

Zack Bornstein with Dr. McKenna and Physicians Assistant, Troy Chandler

UCLA wide receiver and Canadian decathlon standout, Zack Bornstein suffered a hamstring tear 18 months ago. Conventional treatment and therapy were not working so Zack decided to undergo stem cell therapy at Riordan-McKenna Institute in late June 2015. Dr. McKenna treated Zack with precisely guided injections of bone marrow aspirate concentrate (BMAC) harvested with the BioMAC (patent pending) bone marrow aspiration cannula and *AlphGEMS amniotic tissue product.

Complete healing was confirmed by MRI 8 weeks after treatment:

1) No evidence for hamstring strain or denervation and no evidence for tendon tear.
2) No evidence for focal atrophy or hematoma.
3) No osseous abnormalities seen.

After receiving the MRI results, Zack’s father Dean said, “I am not a doctor but looks like you and your procedure has performed a medical miracle! …Thanks for all of your efforts.”

Zack is currently a red shirt freshman at UCLA. He played football at Oaks Christian High School from 2011-’14 and lettered 3 years in football and all 4 years in track. In 2013, Zack was named to the All-Marmonte 2nd team. He played in the FBU Youth All-American game in 2010. In track, he is considered to be one of the top decathletes in the country. Zack competed at the 2013 Pan American Junior Championships in Medellin, Columbia, finishing in 5th place with 7,097 points. In July of 2013, he became the Canadian Junior National Champion (6,918 pts). Zack won the silver medal at the 2013 Arcadia Invitational Decathlon, scoring 6,967 points to set a new California state record for juniors (2nd highest score in California state history). Zack is a 12-time National Champion, 44-time All-American and a member of three National Championship cross country teams.

About Riordan-McKenna Institute (RMI)

RMI specializes in non-surgical treatment of acute and chronic orthopedic conditions using *AlphaGEMS flowable amniotic tissue allograft and bone marrow aspirate concentrate (BMAC) that is harvested using the patented BioMAC bone marrow aspiration cannula. Common conditions treated include meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis. RMI also uses AlphaPATCH amniotic membranes as part of a complete wound care treatment regimen.

RMI also augments orthopedic surgeries with BMAC and AlphaGEMS to promote better post-surgical outcomes.
BMAC contains a patient’s own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. AlphaGEMS is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.

*AlphaGEMS and AlphaPATCH products are produced by Amniotic Therapies Inc. from donated amniotic tissue after normal healthy births. For more information about AlphaGEMS, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/

http://www.rmiclinic.com

801 E. Southlake Blvd.
Southlake, Texas
76092

Tel: (817) 776-8155
Toll Free: (877) 899-7836
Fax: (817) 776-8154

About Amniotic Therapies

Based in Dallas, Texas, Amniotic Therapies specializes in the processing and distribution of human amniotic tissue products for the biologic and regenerative medicine segments of the healthcare market. Amniotic Therapies’ mission is to provide superior human amniotic tissue products that naturally enhance the body’s healing ability, providing patients with improved healing.
Amniotic Therapies is registered with the U.S. Food and Drug Administration (FDA) and is in the process of receiving accreditation from the American Association of Tissue Banks.

http://www.amniotictherapies.com

11496 Luna Rd. Suite 800
Dallas, Texas
75235

Tel: (972) 465-0496

Stem Cells Used to Successfully Treat Chronic Achilles Tendon Injury

Ocala, FL, October 06, 2014 –(PR.com)-Biologic Therapies, Inc. (BTI), a company that specializes in the design and development of medical devices and procedures for the regenerative medicine market, announced today that its products have been used to successfully treat a chronically injured Achilles tendon with stem cell therapy.

A case report, titled ‘Minimally Invasive Autologous Bone Marrow Concentrate Stem Cells in the Treatment of the Chronically Injured Achilles Tendon: A Case Report’, was authored by Biologic Therapies’ Chief Medical Director, Dr. R. Wade McKenna, and Chief Scientific Officer, Dr. Neil H. Riordan, founders of the Riordan-McKenna Institute in Southlake, Texas, USA (www.rmiclinic.com).

The case involved a 56-year-old female patient complaining of a painful “knot” in her left Achilles tendon. The pain limited her ability to perform daily activities such as shopping or being up on her feet for longer than 30 minutes. She had been an active tennis player and recreational athlete, but had not been able to play tennis or jog for ten years. She reported significant pain when relaxing and great pain when walking. The patient had been to multiple physicians and had followed ten years of standard treatment with stretches and anti-inflammatories. She refused multiple offers of invasive surgery that could not promise a return to tennis.

On physical examination by Dr. R. Wade McKenna, the patient had a large, palpable knot in the Achilles tendon, very noticeable and acutely tender. An MRI scan showed severe hypertrophic changes with marked tendinopathy.

The patient received a point-of-care stem cell therapy treatment in Dr. McKenna’s office as an outpatient procedure using Biologic Therapies products. The physician drew bone marrow from her tibia (shin) bone, processed the marrow in a centrifuge to concentrate the stem cells and growth factors, then injected the stem cells and growth factors into and around her injured Achilles tendon. Prior to the injection of the concentrated stem cells and growth factors, an injection of local anesthesia was given to prevent pain. The patient reported little to no pain during or after the procedure.

After six weeks the patient reported no pain at rest and minimal pain while walking. After eight weeks, there was even less pain while walking. The knot was less than 50% of the pre-treatment size and was relatively non-tender to touch. She was back to playing tennis without significant pain or difficulty. After ten weeks the patient was doing much better. An MRI scan showed even more reduction in the size of the knot, and pain was reduced even further. After 32 weeks an MRI scan showed near complete healing of the treated Achilles tendon.

The case report has been published by the scientific journal, CELLR4, the Official Journal of The Cure Alliance. The report can be seen on the CELLR4 website at http://www.cellr4.org/article/1100.

According to Luke Whalen, Biologic Therapies’ CEO, “This is an extremely important development for Biologic Therapies. The case report shows that stem cell therapy is an effective treatment for chronic Achilles tendon injury, which has not been documented before. The report also shows that stem cell therapy for this type of injury can be administered in a physician’s office as a point-of-care outpatient procedure using Biologic Therapies products. There is no need for hospitalization and surgery as would have been the case previously.

“Another important aspect of the publication of this case report is that the scientific journal it was published by is one of the most prestigious publications in the regenerative medicine industry. The members of the CELLR4 Journal Editorial Board that reviewed and approved the report are literally the ‘who’s who’ of regenerative medicine professionals from around the world. We are honored that they chose to publish the report. This helps to reinforce Biologic Therapies’ position as a global leader in regenerative medicine,” said Whalen.

The CELLR4 Editorial Board is led by Editor in Chief, Camillo Ricordi
from the Cell Transplant Center and Diabetes Research Institute at the University of Miami, Miami, Florida, USA. Other editorial staff of note include the Associate Editor for Asia, Jianming Tan
of Fuzhou General Hospital, Xiamen University, China; Assistant Editor, Antonello Pileggi of the Cell Transplant Center and Diabetes Research Institute at the University of Miami, Miami, Florida, USA; and Assistant Board member Arnold I. Caplan
from Case Western Reserve University, Cleveland, Ohio, USA.

In the late 1980’s, Dr. Arnold Caplan and colleagues developed and patented the technology to isolate adult human mesenchymal stem cells (MSCs) from bone marrow and to preserve their multi-potency (Caplan et al., 2001; Koc et al., 1999; Lennon et al., 2006). Adult human MSCs are capable of differentiating into a number of tissue types including bone, cartilage, muscle, marrow, tendon, ligament, adipocytes, and connective tissue.

Over 100 scientists, physicians, researchers and educators from around the world make up the CELLR4 Editorial Board. A complete listing of the Board members can be found at http://www.cellr4.org/editorial-board

About CELLR4
CELLR4 (http://www.cellr4.org) is a scientific journal with particular focus on cellular repair, replacement, regeneration, reprogramming and differentiation. Its scope ranges from fundamental new discoveries in basic science to translational, clinical trials and delivery of novel therapeutic options. As the official journal of the international non-profit organization The Cure Alliance, CELLR4 serves as a platform for discussion of challenges and opportunities on the path to the development of new treatments, independently from the disease target. CELLR4 publishes commentaries and opinion papers on regulatory, legal, and ethical issues, as well as information on global collaborative platforms and funding opportunities of interest to the field.

CELLR4 also serves as the official journal of the Fondazione Cure Alliance Onlus, another non-profit international organization that include physicians, scientists, patients, patient advocates, business and philanthropy leaders, with the mission to promote collaborative efforts worldwide, while addressing and working to resolve impediments and challenges on the path to develop cures for diseases now afflicting humankind. In this direction, the publication serves as a shared communication platform to discuss challenges and opportunities on the path to develop new treatments.

About Biologic Therapies
Based in Ocala, Florida, Biologic Therapies, Inc. (www.biologictherapies.com), is a company with a principal strategy of seeking out and developing innovative, proprietary and patented technologies to meet the needs of the rapidly emerging science of regenerative medicine, including stem cell therapy. Biologic Therapies provides groundbreaking medical technologies that significantly enhance the body’s natural healing ability, thereby providing patients with improved outcomes and quicker restoration of function. The Company’s products provide access to the biologics / regenerative medicine sector of the healthcare market.